SEARCH

SEARCH BY CITATION

Keywords:

  • Cardiac allograft vasculopathy;
  • heart;
  • macrophage;
  • mouse;
  • transplant arteriopathy

Abstract

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgment
  7. References

Cardiac allograft vasculopathy (CAV) is a major source of late posttransplant mortality. Although numerous cell types are implicated in the pathogenesis of CAV, it is unclear which cells actually induce the vascular damage that results in intimal proliferation. Because macrophages are abundant in CAV lesions and are capable of producing growth factors implicated in neointimal proliferation, they are leading end-effector candidates. Macrophages were depleted in a murine heterotopic cardiac transplant system known to develop fulminant CAV lesions. C57BL/6 hearts were transplanted into (C57BL/6 × BALB/c)F1 recipients, which then received anti-macrophage therapy with intraperitoneal carrageenan or i.v. gadolinium. Intraperitoneal carrageenan treatment depleted macrophages by 30–80% with minimal effects upon T, B or NK cells as confirmed by flow cytometry and NK cytotoxicity assays. Carrageenan treatment led to a 70% reduction in the development of CAV, as compared to mock-treated controls (p = 0.01), which correlated with the degree of macrophage depletion. Inhibition of macrophage phagocytosis alone with gadolinium failed to prevent CAV. Macrophages may represent the end-effector cells in a final common pathway towards CAV independent of T-cell or B-cell alloreactivity and exert their injurious effects through mechanisms related to cytokine/growth factor production rather than phagocytosis.

The long-term clinical success of cardiac transplantation is constrained by chronic rejection as manifested by cardiac allograft vasculopathy (CAV). This process is characterized by concentric proliferation of smooth muscle and endothelial cells in the allograft vascular intima, provoking a rapidly progressive and diffuse arteriosclerosis of allograft arteries that often culminates in luminal occlusion of arterial vessels, ischemia-induced replacement fibrosis of the allograft parenchyma and eventual allograft failure (1).

The development of more effective therapies and preventative strategies for CAV has been hindered by an insufficient understanding of many basic aspects of its pathophysiology. It is now clear that there are numerous immunologic and nonimmunologic factors that can promote CAV (1). However, emerging evidence suggests that multiple pathways contributing to vascular lesion formation may all converge on a final common pathway. If so, identifying the end-effector element in the final common pathway and targeting it for treatment may provide the most effective and comprehensive means of eliminating this insidious disease.

Although three pathways to CAV, involving T cells, antibody or NK cells, are well documented (1), it is unclear if they possess the ability to drive the neointimal proliferation and fibrosis observed in CAV lesions. Macrophages are particularly appealing end-effector candidates for several reasons. They are known to widely infiltrate both allografts and CAV lesions themselves (2). They are potently activated by cytokines such as IFN-γ that are produced at high levels by upstream triggers of CAV such as T and NK cells (3). They can produce both reactive oxygen species and potent degradative enzymes which might cause adventitious injury of allograft vascular endothelium (4). Finally, macrophages can produce growth factors such as transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF) and insulin-like growth factor-1 (IGF-1) and chemokines such as MIG/CXCL9 and RANTES/CCL5, all of which might drive the proliferation of neointimal cells (2,5–9). In this study, we evaluate the contribution of macrophages to chronic lesion formation by depleting macrophages from recipients of parental to F1 cardiac transplants, a system that reliably produces CAV lesions, independent of T-cell or antibody alloreactivity (10).

Materials and Methods

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgment
  7. References

Mice

C57BL/6 (H-2b), BALB/c (H-2d) and (C57BL/6 × BALB/c)F1 (H-2b×d) mice were all purchased from The Jackson Laboratory (Bar Harbor, ME). All mice were kept in filter top cages and remained healthy throughout the experiments. All animals were cared for according to American Association for the Accreditation of Laboratory Animal Care approved methods.

Antibodies

Monoclonal antibodies against mouse CD4 (GK1.5, a rat IgG2b) and CD8 (2.43, a rat IgG2b) were produced from cell clones acquired from ATCC (Rockville, MD). Anti-mouse CD49b mAb (DX5, a rat IgM) and anti-mouse F4/80 mAb (CI:A3-1, a rat IgG2b) were purchased from Caltag Laboratories (Burlingame, CA). Anti-mouse CD45/B220 (RA3-6B2, a rat IgG2a) was purchased from BD PharMingen (San Diego, CA). Antibodies used in immunohistochemistry included anti-mouse F4/80 mAb (BM8, eBioscience, San Diego, CA), anti-CD3 (YCD3-1; C.A. Janeway, Yale University), and anti-Ly49G2 (4D11, ATCC).

Murine heart transplantation techniques

Mouse hearts were transplanted to a heterotopic abdominal location with appropriate microsurgical anastomoses according to our previously described technique (11). For parental to F1 transplant experiments, C57BL/6 [B6] donor hearts were transplanted into (C57BL/6 × BALB/c)F1 recipients [designated CB6F1] as described earlier (10). Transplanted hearts were monitored by direct transabdominal palpation at least twice a week. The vigor of contraction of the transplants were recorded on a scale of 0–3+ (10). All transplant recipients received aspirin (Sigma) ad libitum in their water supply (60 mg/L water), starting on the day of transplantation.

Anti-macrophage therapies

Macrophages were either depleted using carrageenan or defunctionalized using gadolinium which blocks phagocytosis. Depletion of macrophages was achieved in transplant recipients with intraperitoneal injections of 1 mg λ-carrageenan type IV (Sigma) dissolved in saline on postoperative day 1, and twice weekly thereafter for the duration of the experiment (12–14). Mice receiving carrageenan all received aspirin anticoagulation, as above, which prevented allograft thrombosis in >85% of transplant recipients. Transplant recipients generally tolerated this regimen well, although almost all developed sterile peritonitis, a known complication of intraperitoneal carrageenan (22,23). Inhibition of macrophage phagocytosis was achieved with i.v. injections of gadolinium(III) chloride (10 mg/kg body weight) on preoperative day -2 and weekly thereafter (12,15). Alternative methods to deplete macrophages using clodronate-encapsulated liposomes (gift of Nico van Rooijen, ref (20)) failed due to systemic thrombosis, which could not be prevented with aspirin, heparin or different liposome batches, but was not observed with saline encapsulated (control) liposomes (data not shown). Apparently, mice are more susceptible to this toxicity than rats (21).

Histological techniques

Transplanted hearts were typically removed from recipients on postoperative day 31 and frozen sections were prepared to determine the presence and degree of CAV, as previously described (16). Sections were prepared with Weigert's elastin stain, and intimal proliferative changes were classified into three stages, as previously reported in detail (16). Immunohistological analysis of tissue macrophages was performed as in previous studies using mAbs directed to the mouse F4/80 pan-macrophage marker (17).

Morphometric analysis

Morphometric analysis, similar to what has been described previously (18), was performed on images of coronary arteries near the ostia on tissue sections stained with Weigert's elastic stain. An image of the most representative section was captured digitally by light microscopy at 100×, 200×, or 400× magnification. IP lab imaging software (Scanalytics, BD Biosciences, Rockville, MD) was used to demarcate the borders of the lumen and the intima of the artery. One evaluator, who was blinded as to the diagnosis and treatment of the hearts, demarcated the areas on all the sections. Tangential arterial sections were demarcated similarly to arterial cross-sections, but in tangential sections demarcation was made on the coronary artery only at the junction of the coronary artery and the aorta. The software then quantitated the manually demarcated luminal and intimal areas. From these area values the ‘neointimal index’, defined as [intimal area/(luminal + intimal area)]× 100, was calculated.

Flow cytometric analysis

Peripheral blood was taken from direct puncture of the inferior vena cava at the time of sacrifice, and peripheral blood leukocytes (PBLs) were isolated following two rounds of water osmolysis of erythrocytes. Nonspecific FcR binding was blocked by anti-mouse FcR mAb 2.4G2 (BD PharMingen) and the PBLs were then washed and incubated with fluorophore-conjugated antibodies specific for F4/80, CD3, DX5 and B220. All incubations were performed for 30 min at 4°C, using 100 μL staining volumes and 500 000 cells per staining reaction. Lymphocytes were analyzed on a FACScan (Becton Dickinson, San Jose, CA).

NK cell cytotoxicity assay

A FACS-based cytotoxicity assay was used as previously described (19). Briefly, YAC target cells were labeled with DiOC18(3) membrane stain for 20 min at 37°C. Simultaneously, splenocytes were recovered from cardiac transplant recipients and prepared with ACK lysing buffer. Labeled YAC target cells were then coincubated for 3 h at 37°C with effector splenocytes at effector:target ratios ranging from 1:2.5 to 80:1, prepared in duplicate. Negative controls of target cells alone and positive controls of target cells treated with 0.1% saponin were also prepared. Following incubation, all samples were stained with membrane-impermeable propidium iodide dye, which only labeled the dead cells. Samples were analyzed on a FACScan (Becton Dickinson), comparing double-staining cells (dead targets) to all cells staining with DiOC18(3) and correcting for spontaneous and max lysis. Cytotoxicity curves were obtained by plotting %adjusted target cell lysis versus actual splenocyte:target ratios. Assay was repeated three times, with representative cytotoxicity curves depicted.

Statistical analysis

Significant differences between group means were determined using the Fisher's exact test. A p-value of <0.05 was considered significant.

Results

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgment
  7. References

To evaluate the participation of macrophages in CAV pathogenesis, we employed our previously characterized parental to F1 transplant system, involving the heterotopic transplantation of hearts from C57BL/6 donors into (C57BL/6 × BALB/c)F1 hybrid (CB6F1) recipients. This transplant combination consistently produces CAV lesions within 21 days through an alloresponse involving both recipient NK and T cells (10). Moreover, the parental to F1 transplant system does not require the use of potentially confounding immunosuppressive agents to prevent acute allograft rejection.

Carrageenan treatment depletes macrophages in transplant recipients

Flow cytometry was performed on transplant recipients at the time of sacrifice (POD 30) to verify the selectivity of carrageenan-mediated macrophage depletion. Compared to control transplant recipients treated with aspirin alone, carrageenan treatment resulted in a notable 30–80% depletion of macrophages in peripheral blood leukocytes (Figure 1A). The effect of carrageenan on other cell populations such as NK and B-cell populations was negligible, with only a mild (≈20%) depletion of T cells being observed (Figures 1B). The total number of leukocytes extracted from the spleen and peripheral blood of carrageenan-treated recipients was almost identical to those of controls indicating that changes in cell population proportions reflect changes in absolute cell counts (data not shown).

image

Figure 1. (A) Carrageenan causes specific macrophage depletion. Three-color FACS analysis was employed to study the representation of leukocyte sub-populations in PBLs extracted from parental to F1 transplant recipients either treated with both carrageenan and aspirin (n =7) or else treated with aspirin alone (n = 3). Carrageenan treatment resulted in prominent macrophage depletion (p < 0.05), mild T-cell depletion (p < 0.05), and no depletion of NK or B cells. FACS markers analyzed: macrophages (F4/80+), T cells (CD3+ DX5−), NK cells (CD3− DX5+), B cells (B220+). Error bars reflect one standard error of mean. (B) Carrageenan depletes macrophages. Using the FACS analysis results obtained above, mean proportions of macrophages, T cells, NK cells and B cells were obtained for both carrageenan-treated transplant recipients (n = 7) and controls treated with aspirin alone (n = 3). These averages were compared to calculate the % depletion in individual leukocyte sub-populations achieved by carrageenan treatment. Error bars reflect one standard error of mean.

Download figure to PowerPoint

Due to our recent finding that NK cells are important triggers of CAV formation in this parental to F1 transplant system (10), it was necessary to exclude the possibility that carrageenan treatment affected NK cell number or function. Flow cytometry confirmed that carrageenan treatment did not affect the numbers of NK cells in the circulation and spleen (Figure 1A). Furthermore, a comparison of splenocyte effectors from either control transplant recipients (treated with aspirin alone) or carrageenan-treated recipients revealed no significant difference in NK cytotoxicity against YAC target cells (Figure 2).

image

Figure 2. Carrageenan treatment does not inhibit NK cell function. An FACS-based NK cytotoxicity assay was performed to compare NK cytotoxicity in carrageenan-treated transplant recipients with control recipients treated with aspirin alone. This graph depicts representative cytotoxicity curves for the carrageenan-treated and control groups.

Download figure to PowerPoint

Macrophage depletion suppresses CAV formation

The effects of macrophage depletion on CAV formation were assessed by comparing F1 recipients of parental hearts treated with aspirin and carrageenan to F1 controls treated with aspirin alone. All recipients were sacrificed on postoperative day 30, as earlier studies with this transplant system identified initial CAV development by postoperative day 21 (10). Transplanted hearts continued to beat vigorously up to the day of sacrifice and showed no signs of acute rejection (Table 1).

Table 1.  Carrageenan-mediated macrophage depletion suppresses CAV formation
GroupDonorRecipientTreatmentHearts with CAV5Neointimal index7
  1. 1Aspirin given in recipient water supply ad libitum (60 mg/L water), starting on day of transplant.

  2. 2Intraperitoneal injection of 1 mg carrageenan given on postoperative day +1 and twice weekly thereafter, along with above aspirin regimen.

  3. 3Intraperitoneal injection of 1 mg carrageenan started on postoperative day +30 and twice weekly thereafter, along with above aspirin regimen. Transplant recipients sacrificed on postoperative day 51.

  4. 4Gadolinium(III) chloride (10 mg/kg body weight) administered i.v. via dorsal penile vein injection on preoperative day -2 and weekly thereafter.

  5. 5All transplanted hearts continued to beat vigorously at time of recipient sacrifice.

  6. 6p < 0.01 compared to aspirin-only controls in group 3.

  7. 7Mean neointimal index ± standard error. Neointimal index =[intimal area/(luminal + intimal area)]× 100.

  8. 8p < 0.001 compared to aspirin-only controls in group 3.

1C57BL/6C57BL/6None0/7 
2CB6F1CB6F1None0/510.7 ± 2.3
3C57BL/6CB6F1Aspirin only16/678.2 ± 6.9
4C57BL/6CB6F1Carrageenan + aspirin23/106  26.8 ± 10.18
5C57BL/6CB6F1Delayed carrageenan34/4 
6C57BL/6CB6F1Gadolinium46/6 

All parental to F1 transplants treated with aspirin alone showed evidence of fulminant vasculopathy whereas no isografts developed lesions (Table 1, groups 1–3). Previous results showing that parental to F1 transplants receiving no treatment also develop CAV indicate that CAV in this system is not a consequence of aspirin administration (10). Each arterial lesion exhibited collagen and smooth muscle cell accumulation, often resulting in near complete luminal occlusion (Figure 3B). Cuffs of infiltrating cells were present around affected vessels, although there was little or no accompanying inflammation in the myocardium. These lesions reproduced with fidelity the vascular lesions observed in human heart transplant recipients undergoing chronic rejection.

image

Figure 3. Immunohistochemistry of proximal coronary arteries from parental to F1 hybrid cardiac transplants. (A) Coronary artery emerging from aorta shows no CAV in a recipient treated with both carrageenan and aspirin following sacrifice on postoperative day +30. (B) Control transplant recipients treated with aspirin alone developed fulminant CAV lesions by postoperative day +30, as shown in this Weigert's elastin stain. Note the almost complete luminal occlusion caused by neointimal proliferation. Arrowheads mark the original boundaries of this vessel. (C) F4/80 staining of a carrageenan-treated transplant recipient that failed to develop CAV shows diminished perivascular infiltrating macrophages compared to abundant macrophage infiltration seen in (D) aspirin-only controls. Arrowheads mark the original boundaries of this vessel. (E) Carrageenan treatment failed to reverse established CAV lesions in allograft coronary arteries when administered for 3 weeks, starting 30 days posttransplant. (F) Intravenous gadolinium chloride failed to prevent the onset of CAV, despite their ability to inhibit macrophage phagocytosis. Note concentric hyperplasia of the intima of this coronary artery, visualized with Weigert's elastin stain.

Download figure to PowerPoint

In striking contrast, only 3 of 10 carrageenan-treated transplant recipients developed lesions of CAV (Table 1, group 4). Histological analysis showed that most of these macrophage-depleted recipients had pristine allograft coronary arteries with no evidence of vasculopathy (Figure 3A), a notable difference from the aspirin-only controls (Figure 3B). Quantitative assessment of the coronary arteries with computerized morphometry analysis verified that macrophage depletion with carrageenan substantially suppresses the formation of neointimal proliferation compared to controls treated with aspirin alone (Table 1). Importantly, the mild T-cell depletion observed with carrageenan treatment did not likely contribute to the observed abrogation of CAV because earlier studies demonstrated that treatment of these transplant recipients with anti-CD4 and anti-CD8 mAbs (achieving >90% T-cell depletion) could not prevent CAV (10). Immunohistochemistry revealed collections of macrophages surrounding coronary vessels in both carrageenan-treated and control transplant recipients, although the macrophage-specific F4/80 staining was far more intense in the controls (Figures 3C and 3D). The presence of infiltrating macrophages in carrageenan-treated recipients demonstrates the limitations of macrophage depletion achieved by this regimen. However, the degree of macrophage depletion in the three carrageenan-treated recipients that did develop vascular lesions was significantly less than in those that did not develop vasculopathy (p < 0.05), suggesting that abrogation of CAV correlated directly with the degree of macrophage depletion achieved (Figure 4). Infiltrating CD3+ T cells were also noted in both groups (data not shown).

image

Figure 4. Extent of macrophage depletion in carrageenan-treated transplant recipients correlates with absence of CAV. Using the earlier FACS analysis of macrophage-specific F4/80 surface expression, the average proportion of macrophages in peripheral blood was calculated for control transplant recipients (treated with aspirin alone), carrageenan-treated recipients who progressed to develop CAV (mean neointimal index = 65.2 ± 6.9) and carrageenan-treated recipients who suppressed CAV formation (mean neointimal index = 7.6 ± 3.5). Error bars reflect one standard error of mean.

Download figure to PowerPoint

Delayed treatment had no effect on CAV lesion formation

To determine whether delayed macrophage depletion could reverse established CAV lesions, parental to F1 cardiac transplant recipients were treated with a 3-week course of carrageenan starting on postoperative day 30, by which time CAV lesions should have already formed in the allografts (Table 1, group 5). Upon sacrifice, all four of the recipients receiving this delayed carrageenan regimen showed evidence of persistent vasculopathy (Figure 3E).

Inhibition of macrophage phagocytosis fails to abrogate CAV

In order to distinguish mechanisms by which macrophages may mediate the pathogenesis of CAV, we treated transplant recipients with i.v. gadolinium chloride. Unlike carrageenan, gadolinium specifically inhibits macrophage phagocytosis without causing depletion (12,15). Treatment of parental to F1 cardiac transplant recipients with gadolinium chloride failed to suppress CAV in six of six recipients (Table 1, group 6). The morphology of lesions in the gadolinium-treated recipients closely resembled those observed in untreated controls, showing an advanced degree of neointimal proliferation (Figure 3F). Of note, treatment with gadolinium did not deplete splenic macrophages (data not shown). This finding suggests that the role of macrophages in promoting CAV is independent of phagocytosis or antigen-presentation.

Discussion

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgment
  7. References

We have demonstrated that depleting host macrophages with carageenen can suppress the development of CAV in a parental to F1 heterotopic cardiac transplant system. The success of this strategy was correlated with the degree of macrophage depletion achieved. While apparently critical for the initial pathogenesis of CAV, macrophages did not appear to be required for the maintenance of established CAV lesions, as delayed treatment had no effect on lesion development. Finally, the ability of macrophages to promote CAV formation was likely related to cytokine or growth factor release rather than phagocytosis or antigen presentation, as selective inhibition of macrophage phagocytosis with gadolinium chloride could not prevent CAV. Together, these findings suggest a role for macrophages in the pathogenesis of CAV, possibly as end-effectors in a final common pathway toward CAV. To our knowledge, this present work marks the first demonstration that specific macrophage depletion can suppress CAV formation in an unmanipulated vascularized organ transplant system.

The precise contribution of macrophages to the pathogenesis of transplant vasculopathy is ill-defined in the literature. While macrophages are abundantly present in CAV lesions (2) and cytokines associated with macrophage activation are upregulated during CAV development (3), it remains unproven whether this is a cause or effect of CAV. Earlier reports have failed to establish a definitive causal link between macrophages and CAV, in part due to the difficulties of achieving selective macrophage inhibition or depletion. Although treatment of murine transplant recipients with purported macrophage inhibitors such as gamma-lactone and 15-deoxyspergualin managed to partially suppress transplant vasculopathy, the specificity and precise effects of these agents on macrophages are unknown (24,25). The severe reduction of vasculopathy observed with experimental transplants using the supposedly macrophage-deficient op/op osteopetrotic mice as recipients is also raised to implicate macrophages in CAV formation (26). The op/op mouse, however, also suffers from pleiotrophic immune defects such as aberrant granulocyte function, impaired Th1 differentiation and irregular B-cell lymphopoeisis (27–29). These confounding immune defects prevented the definitive interpretation of transplant experiments utilizing op/op mice, leaving the actual role of macrophages in CAV pathogenesis unresolved. The findings of this study help establish a firmer link between macrophages and CAV.

A more comprehensive examination of macrophage activation pathways and effector functions would be required to identify specific mechanisms by which macrophages may contribute to allograft vasculopathy. However, several distinct pathways of macrophage activation and function have been elucidated in recent years which have potential relevance to CAV. Classical activation of macrophages requires the dual stimulation of macrophages by IFN-γ and engagement of their toll-like receptors (TLRs) (30,31). Organ transplantation might induce the classical activation of macrophages, as IFN-γ is abundantly produced by the activated T cells and NK cells that infiltrate allografts in the early postoperative period, and macrophage TLRs recognize ligands such as heat shock proteins and altered lipoproteins that are liberated from allograft cells damaged by ischemia-reperfusion injury (32–34). An alternative activation pathway for macrophages was also recently described. This pathway develops in the setting of a local cytokine milieu enriched in IL-4 and/or IL-13, cytokines traditionally associated with a TH2-type immune response (31). Macrophages activated via the alternative pathway have a less robust respiratory burst response, but they instead promote angiogenesis and proliferation of vascular endothelium, characteristics which might facilitate macrophage involvement in CAV pathogenesis (31,35).

Once activated by organ transplantation, recipient macrophages possess three distinct sets of effector functions which may enable them to promote allograft arteriopathy. First, their phagocytic properties and constitutive expression of MHC class II products establish macrophages as excellent antigen-presenting cells to CD4+ T cells, although their failure to constitutively express costimulatory molecules prevents them from activating naïve T cells (32). Through the presentation of donor MHC peptides, macrophages may contribute to the indirect allorecognition pathway, culminating in smoldering sub-acute alloresponses that are implicated in vasculopathy development (36). Macrophage facilitation of the adaptive immune alloresponse is also promoted by production of chemokines such as RANTES/CCL5 and MIG/CXCL9. However, increased leukocyte recruitment and donor antigen presentation by macrophages cannot be invoked as the dominant mechanism by which macrophages contribute to CAV formation, as inhibition of macrophage phagocytosis and antigen presentation with gadolinium chloride administration failed to suppress allograft vasculopathy.

Next, activated macrophages may directly injure allograft vascular endothelium through the release of reactive oxygen species. Injury of this vascular endothelium is hypothesized to be the common insult that underpins all causes of CAV, perhaps through a pathway involving dysregulation of endothelial nitric oxide production (37). Finally, in addition to inducing direct vascular endothelial injury, macrophages may promote an aberrant healing response fostering allograft arteriopathy through the production of a large array of growth factors (such as PDGF, IGF-1 and TGF-β). Many of these growth factors are known to promote vascular smooth muscle proliferation and migration, essential steps in the evolution of the neointimal proliferation that characterizes CAV (2,5–7).

This study has several limitations. First, the peritonitis induced by carrageenan is associated with granulocytosis (38), so the possibility cannot be fully excluded that CAV suppression was caused by neutrophil-produced protective factors rather than macrophage depletion. Additionally, while carrageenan has been employed extensively in the literature to induce selective macrophage depletion, the possibility that carrageenan may deplete other immune cells (particularly other phagocytic cell lineages such as dendritic cells) was not specifically examined, and therefore the suppression of CAV may not actually result from macrophage depletion. However, the leukocyte subsets most relevant to transplant rejection (including T cells, B cells and NK cells) were examined, and minimal adventitious effects on these cell lineages were noted following carrageenan administration.

Next, while evidence that macrophages promote CAV through growth factor release is suggestive, these findings cannot definitively prove that macrophages function as end-effectors in CAV pathogenesis rather than as intermediaries in this process. Other cell populations implicated in CAV (such as T, B and NK cells) might instead serve as both triggers and end-effectors in the CAV cascade. Supporting this hypothesis, both NK and T cells can produce abundant IFN-γ, a cytokine which may be sufficient for CAV formation (39). However, other studies have cast doubt on the premise that IFN-γ can induce neointimal proliferation by itself (10). The final notable limitation of this study involves its use of a single specific system of CAV formation (the parental to F1 hybrid transplant system) which may not be fully relevant to CAV lesions attained in clinical transplantation, despite the verisimilitude of the CAV lesions developed in this experimental system. This well-characterized transplant system was selected because it offered several unique advantages for the purposes of this study, including the rapid development of almost universal allograft vasculopathy and freedom from acute alloresponses, eliminating a requirement to use a potentially confounding immunosuppressant regimen.

Multiple lines of evidence support a role for macrophages in chronic alloresponses against other solid organ grafts. For example, the intensity of macrophage infiltration in early biopsies of human renal allografts is predictive of subsequent development of fibrosis (40). In miniature swine, persistence of macrophage infiltration following the resolution of an episode of acute rejection also predicted the ultimate evolution of chronic renal allograft rejection (41). An anti-macrophage regimen (gadolinium) also was able to suppress the development of bronchiolitis obliterans, the manifestation of chronic rejection in lung transplants, in a rat model of heterotopic tracheal transplantation (42). Furthermore, our studies complement a growing body of evidence implicating macrophages in clinical vasculopathy arising outside the setting of organ transplantation. Macrophage depletion partially ameliorates the neointimal proliferation seen in vein grafts and in animal models of balloon angioplasty (43–45). Thus, the therapeutic implications of these findings may have broader applicability in the field of transplantation and vascular biology.

It is notable that CAV arises despite long-term immunosuppression that is effective in preventing acute rejection. Macrophages are not specifically targeted by calcineurin inhibitors (46), but rapamycin partially inhibits macrophage proliferation in response to macrophage colony-stimulating factor (M-CSF) (47). Rapamycin also suppresses monocyte chemotaxis into tissues, hindering their development into macrophages (48). Perhaps not coincidentally, rapamycin is able to reduce the incidence of CAV in human heart transplant recipients more than twofold compared to other conventional immunosuppressants (49). These results therefore offer the hope that specifically targeted macrophage inactivation or depletion in humans may improve the long-term outcome of transplanted organs.

Acknowledgment

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgment
  7. References

We thank Dr. Bruce Rosengard for critical review of this manuscript. This work was funded in part by grants from the National Heart Blood and Lung Institute of the National Institutes of Health (RO1 HL071932) and a grant from the Roche Organ Transplant Research Foundation. W.H.K. is a Howard Hughes Medical Institute Research Training Fellow.

References

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgment
  7. References
  • 1
    Weis M, Von Scheidt W. Coronary artery disease in the transplanted heart. Annu Rev Med 2000; 51: 81100.
  • 2
    Hutchinson IV. Cardiac allograft vasculopathy–the cellular attack. Z Kardiol 2000; 89(Suppl 9): 1620.
  • 3
    Russell ME, Wallace AF, Hancock WW et al. Upregulation of cytokines associated with macrophage activation in the Lewis-to-F344 rat transplantation model of chronic cardiac rejection. Transplantation 1995; 59: 572578.
  • 4
    Libby P, Pober JS. Chronic rejection. Immunity 2001; 14: 387397.
  • 5
    Alpers CE, Davis CL, Barr D, Marsh CL, Hudkins KL. Identification of platelet-derived growth factor A and B chains in human renal vascular rejection. Am J Pathol 1996; 148: 439451.
  • 6
    Hayry P, Myllarniemi M, Aavik E et al. Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat. FASEB J 1995; 9: 13361344.
  • 7
    Sihvola R, Koskinen P, Myllarniemi M et al. Prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. Circulation 1999; 99: 22952301.
  • 8
    Yun JJ, Fischbein MP, Whiting D et al. The role of MIG/CXCL9 in cardiac allograft vasculopathy. Am J Pathol 2002; 161: 13071313.
  • 9
    Yun JJ, Fischbein MP, Laks H et al. Rantes production during development of cardiac allograft vasculopathy. Transplantation 2001; 71: 16491656.
  • 10
    Uehara S, Chase CM, Kitchens WH et al. NK cells can trigger allograft vasculopathy: The role of hybrid resistance in solid organ allografts. J Immunol 2005; 175: 34243430.
  • 11
    Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K and non-H-2 antigen in rejections. Transplantation 1973; 16: 343350.
  • 12
    Goldmann O, Rohde M, Chhatwal GS, Medina E. Role of macrophages in host resistance to group A streptococci. Infect Immun 2004; 72: 29562963.
  • 13
    Debrick JE, Campbell PA, Staerz UD. Macrophages as accessory cells for class I MHC-restricted immune responses. J Immunol 1991; 147: 28462851.
  • 14
    Allison AC, Harington JS, Birbeck M. An examination of the cytotoxic effects of silica on macrophages. J Exp Med 1966; 124: 141154.
  • 15
    Adding LC, Bannenberg GL, Gustafsson LE. Basic experimental studies and clinical aspects of gadolinium salts and chelates. Cardiovasc Drug Rev 2001; 19: 4156.
  • 16
    Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. I. Time course, immunogenetic and immunopathological considerations. Am J Path 1994; 144: 260274.
  • 17
    Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. III. Effects of recipient treatment with a monoclonal antibody to interferon-g. Transplantation 1994; 57: 13671371.
  • 18
    Armstrong AT, Strauch AR, Starling RC, Sedmak DD, Orosz CG. Morphometric analysis of neointimal formation in murine cardiac allografts. Transplantation 1997; 63: 941947.
  • 19
    Piriou L, Chilmonczyk S, Genetet N, Albina E. Design of a flow cytometric assay for the determination of natural killer and cytotoxic T-lymphocyte activity in human and in different animal species. Cytometry 2000; 41: 289297.
  • 20
    Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: Mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994; 174: 8393.
  • 21
    Takayama J, Koyamada N, Abe T et al. Macrophage depletion prevents accelerated rejection and results in long-term survival in hamster to rat cardiac xenotransplantation. Transplant Proc 2000; 32: 1016.
  • 22
    Oliani SM, Paul-Clark MJ, Christian HC, Flower RJ, Perretti M. Neutrophil interaction with inflamed postcapillary venule endothelium alters annexin I expression. Am J Pathol 2001; 158: 603615.
  • 23
    DeSimone JM, Meguid MM, Kurzer M, Westervelt J. Indomethacin decreases carrageenan-induced peritoneal adhesions. Surgery 1998; 104: 788795.
  • 24
    Azuma H, Nadeau KC, Ishibashi M, Tilney NL. Prevention of functional, structural, and molecular changes of chronic rejection of rat renal allografts by a specific macrophage inhibitor. Transplantation 1995; 60: 15771582.
  • 25
    Raisanen-Sokolowski A, Yilmaz S, Tufveson G, Hayry P. Partial inhibition of allograft arteriosclerosis (chronic rejection) by 15-deoxyspergualin. Transplantation 1994; 57: 17721777.
  • 26
    Shi C, Lee WS, He Q et al. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci U S A 1996; 93: 40514056.
  • 27
    Guleria I, Pollard JW. Aberrant macrophage and neutrophil population dynamics and impaired Th1 response to listeria monocytogenes in colony-stimulating-factor-1-deficient mice. Infect Immunol 2001; 69: 1951807.
  • 28
    Lu L, Osmond DG. Regulation of cell survival during B lymphopoiesis in mouse bone marrow: Enhanced pre-B-cell apoptosis in CSF-1-deficient op/op mutant mice. Exp Hematol 2001; 29: 596601.
  • 29
    Wiktor-Jedrzejczak W. In vivo role of macrophage growth factors as delineated using CSF-1 deficient op/op mouse. Leukemia 1993; 7(Suppl 2):S117S121.
  • 30
    Mackaness GB. The Immunological Basis of Acquired Cellular Resistance. J Exp Med 1964; 120: 105120.
  • 31
    Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 2335.
  • 32
    Wyburn KR, Jose MD, Wu H, Atkins RC, Chadban SJ. The role of macrophages in allograft rejection. Transplantation 2005; 80: 16411647.
  • 33
    Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 2002; 277: 1510715112.
  • 34
    Zhai Y, Shen XD, O'Connell R et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol 2004; 173: 71157119.
  • 35
    Kodelja V, Muller C, Tenorio S, Schebesch C, Orfanos CE, Goerdt S. Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology 1997; 197: 478493.
  • 36
    Hornick PI, Mason PD, Baker RJ et al. Significant frequencies of T cells with indirect anti-donor specificity in heart graft recipients with chronic rejection. Circulation 2000; 101: 24052410.
  • 37
    Weis M, Cooke JP. Cardiac allograft vasculopathy and dysregulation of the NO synthase pathway. Arterioscler Thromb Vasc Biol 2003; 23: 567575.
  • 38
    Hurtrel B, Lagrange PH. Comparative effects of carrageenan on systemic candidiasis and listeriosis in mice. Clin Exp Immunol 1981; 44: 355358.
  • 39
    Tellides G, Tereb DA, Kirkiles-Smith NC et al. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature 2000; 403: 207211.
  • 40
    Pilmore HL, Painter DM, Bishop GA, McCaughan GW, Eris JM. Early up-regulation of macrophages and myofibroblasts: A new marker for development of chronic renal allograft rejection. Transplantation 2000; 69: 26582662.
  • 41
    Shimizu A, Yamada K, Sachs DH, Colvin RB. Mechanisms of chronic renal allograft rejection. II. Progressive allograft glomerulopathy in miniature swine. Lab Invest 2002; 82: 673686.
  • 42
    Oyaizu T, Okada Y, Shoji W et al. Reduction of recipient macrophages by gadolinium chloride prevents development of obliterative airway disease in a rat model of heterotopic tracheal transplantation. Transplantation 2003; 76: 12141220.
  • 43
    Hoch JR, Stark VK, Van Rooijen N, Kim JL, Nutt MP, Warner TF. Macrophage depletion alters vein graft intimal hyperplasia. Surgery 1999; 126: 428437.
  • 44
    Danenberg HD, Fishbein I, Gao J et al. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 2002; 106: 599605.
  • 45
    Danenberg HD, Golomb G, Groothuis A et al. Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation 2003; 108: 27982804.
  • 46
    Drath DB, Kahan BD. Phagocytic cell function in response to immunosuppressive therapy. Arch Surg 1984; 119: 156160.
  • 47
    Comalada M, Valledor AF, Sanchez-Tillo E, Umbert I, Xaus J, Celada A. Macrophage colony-stimulating factor-dependent macrophage proliferation is mediated through a calcineurin-independent but immunophilin-dependent mechanism that mediates the activation of external regulated kinases. Eur J Immunol 2003; 33: 30913100.
  • 48
    Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: Inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol 2005; 46: 481486.
  • 49
    Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847858.